Zusammenfassung
Die Erkenntnis, dass die Sicherstellung einer ausreichenden Selenversorgung einen
wesentlichen Beitrag zur Prävention und Therapie von Autoimmunthyreopathien leistet,
zählt zu den wichtigsten Innovationen in der Thyreologie der letzten Jahre. Mehrere
publizierte Studien dokumentieren bei der Immunthyreoiditis Hashimoto eine therapeutische
und präventive Wirkung, wenn die konventionelle Gabe von L-Thyroxin mit Selen in therapeutischer
Dosierung (200 μg/d) kombiniert wird. Bislang noch nicht publizierte Daten bestätigen
den Nutzen einer ausreichend hohen Selenzufuhr auch bei der zweiten wichtigen Immunthyreopathie,
dem Morbus Basedow, sowie der damit eng assoziierten endokrinen Orbitopathie.
Summary
Provision of adequate selenium supply has recently been recognized as a fundamental
step towards better treatment and prevention of autoimmune thyroid disorders. As documented
by at least two randomized controlled clinical studies, addition of sufficient amounts
of selenium (200 μg/d) to conventional replacement with levothyroxine will improve
the clinical and immunological course of patients with Hashimoto's thyroiditis. Moreover,
yet unpublished data suggest that therapeutic doses of selenium will also improve
the course of patients with Graves' disease, and most notably, of those afflicted
by the closely associated condition of active ophthalmopathy.
Schlüsselwörter
Immunthyreoiditis - Hashimoto-Thyreoiditis - Morbus Basedow - endokrine Orbitopathie
- Selen - Immunregulation
Key words
Thyroiditis - Hashimoto's disease - Graves' disease - thyroid-associated ophthalmopathy
- selenium - immunoregulation
Literatur
- 1
Bianco A C, Salvatore D, Gereben B, Berry M J, Larsen P R.
Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine
selenodeiodinases.
Endocr Rev.
2002;
23
38-89
- 2
Bjorkman U, Ekholm R.
Accelerated exocytosis and H2O2 generation in isolated thyroid follicles enhance protein
iodination.
Endocrinology.
1984;
115
392-398
- 3
Contempre B, Dumont J E, Denef J F, Many M C.
Effects of selenium deficiency on thyroid necrosis, fibrosis and proliferation: a
possible role in myxedematous cretinism.
Eur J Endocrinol.
1995;
133
99-109
- 4
Contempre B, Le-Moine O, Dumont J E, Denef J F, Many M C.
Selenium deficiency and thyroid fibrosis. A key role for macrophages and transforming
growth factor beta (TGF-beta).
Mol Cell Endocrinol.
1996;
124
7-15
- 5
Derumeaux H, Valeix P, Castlebon K. et al .
Association of selenium with thyroid volume and echostructure in 35- to 60-year-old
French adults.
Eur J Endocrinol.
2003;
148
309-315
- 6
Duntas L H, Mantzou E, Koutras D A.
Effects of six month treatment with selenomethionine in patients with autoimmune thyroiditis.
Europ J Endocrinol.
2003;
148
389-393
- 7
Gärtner R, Gasnier B CH.
Selenium in the treatment of autoimmune thyroiditis.
BioFactors.
2003;
19
165-170
- 8
Gärtner R, Gasnier B CH, Dietrich J W, Krebs B, Angstwurm M WA.
Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid
peroxidase antibody concentrations.
J Clin Endocrinol Metab.
2002;
87
1687-1691
- 9
Holben D H, Smith A M.
The diverse role of selenium within selenoproteins: a review.
J Am Diet Assoc.
2000;
100
836-843
- 10
Huang W, Kukes G D.
Hashimoto's thyroiditis: An organ-specific autoimmune disease - pathogenesis and recent
developments.
Laboratory Invest.
1999;
79
1175-1180
- 11
Köhrle J, Brigelius-Flohé R, Böck A. et al .
Selenium in biology: facts and medical perspectives.
Biol Chem.
2000;
381
849-864
- 12
Nakamura Y, Ohtaki S, Makino R, Tanaka T, Ishimura Y.
Superoxide anion is the initial product in the hydrogen peroxide formation catalysed
by NADPH oxidase in porcine thyroid plasma membranes.
J Biol Chem.
1989;
264
4759-4761
- 13
Rayman M P.
The importance of selenium to human health.
Lancet.
2000;
356
233-241
- 14
Schmidt K J, Bayer W, Schweizer T, Hewel T, Schmidt K H.
Selensubstitution - ein therapeutischer Ansatz bei Schilddrüsenerkrankungen.
VitaMinSpur.
1998;
13
33-39
- 15
Weetman A.
Autoimmune thyroid disease: propagation and progression.
Eur J Endocrinol.
2003;
148
1-9
1 Nachdruck aus Erfahrungsheilkunde 2005; 54:621-625 mit freundlicher Genehmigung.
Prof. Dr. med. Armin E. Heufelder
Internist und Endokrinologe
Elisenstr. 3A
80335 München
Email: endoc@web.de